ScreenerHero

VCRE Vicore Pharma Holding AB (publ)

NAS · US · Healthcare · Biotechnology · vicorepharma.com
8.660USD-0.92%Mkt Cap: 243.90M $P/E: —

Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap243.90M USD
Enterprise Value—
Revenue (TTM)—
Gross Profit3.82M USD
Net Income (TTM)-477.47M USD
Revenue/Share—
Last Price8.660 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees46
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B—
EPS (TTM)-2.04
EPS (Forward)—
52W Range
8.3903% of range17.80
52W High17.80 USD
52W Low8.390 USD
Profitability
Gross Margin100.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin-12509.14%
ROE-43.59%
ROA-39.18%
Growth
Revenue Growth26.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-375.74M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-116.02%
Net Debt—
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio12.68
Quick Ratio12.50
Book Value/Sh—
Cash/Share—
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)33.15 USD
Upside (mean)+282.8%
Target Range33.15 USD – 33.15 USD
# Analysts1
Ownership
Shares Out.28.16M
Float19.86M
Insiders0.00%
Institutions1.28%
Short Interest
Short Ratio0.7d
Short % Out.0.04%
Shares Short9.86K
Short (prev mo.)11.13K
Technical
SMA 5011.14 (-22.2%)
SMA 20011.51 (-24.8%)
Beta0.09
S&P 52W Chg15.78%
Avg Vol (30d)26.36K
Avg Vol (10d)34.30K
Technical Indicators
RSI (14)20.4
MACD-0.6817
MACD Signal-0.6007
MACD Hist.-0.0809
BB Upper11.50 USD
BB Middle9.953 USD
BB Lower8.402 USD
BB Width31.15%
ATR (14)0.6143 USD
Vol Ratio (20d)0.96x